No Data
No Data
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Express News | Guojin Securities: Focus on opportunities such as in vitro diagnostic collection clean-up and proprietary Chinese medicine collection
Express News | Capital Securities: The high dividend rate in the Chinese medicine industry is stable and sustainable
Have Insiders Sold Modern Chinese Medicine Group Shares Recently?
We wouldn't blame Modern Chinese Medicine Group Co., Ltd. (HKG:1643) shareholders if they were a little worried about the fact that Xinlei Sun, the Executive Chairman recently netted about HK$18m sell
Modern Biotechnology Group Holdings Co., Ltd. OTC sale of 48 million shares of Modern Chinese Medicine Group (01643.HK) common shares worth approximately HK$18 million
On March 27, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 27, Modern Biotechnology Group Holdings Co., Ltd. Modern Biotechnology Group Holdings Limited sold $48 million of $Modern Chinese Medicine Group (01643.HK) common shares worth approximately HK$18 million on March 21 at an average price of HK$0.375 per share. After the sale, Modern Biotechnology Group Holdings Co., Ltd.
Modern Chinese Medicine Group (01643.HK) profit before tax fell 45.1% to 68.3 million yuan in 2023
Gelonghui March 22 | Modern Chinese Medicine Group (01643.HK) announced that for the year ended December 31, 2023, the Group recorded revenue of approximately RMB 344.1 million in 2023, a decrease of approximately RMB 55.6 million or 13.9% compared with the fiscal year ending 2022. The decline in revenue was mainly due to changes in government policies, which led to a decrease in orders from dealers. Profit before tax decreased by about 45.1% from about RMB 124.3 million in 2022 to about RMB 68.3 million as of 2023, mainly due to changes in government policies, the decrease in dealer orders
No Data